<DOC>
	<DOC>NCT02855164</DOC>
	<brief_summary>The purpose of the study is to assess the effects of different doses of LJN452 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH</brief_summary>
	<brief_title>Safety, Tolerability and Efficacy Study of 12 Weeks LJN452 Treatment in NASH Patients</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>male/female patients, 18 years or older written informed consent presence of NASH by histological evidence (liver biopsy) and elevated alanine aminotransferase (ALT) OR phenotypic diagnosis based on elevated ALT, BMI and diagnosis of Type 2 diabetes mellitus (DM) Liver fat equal to or higher than 10% by MRI previous exposure to OCA patients taking prohibited medications pregnant or nursing (lactating) women current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening uncontrolled diabetes mellitus presence of cirrhosis hepatic decompensation or severe liver impairment previous diagnosis of other forms of chronic liver disease patients with contraindications to MRI imaging</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LJN452</keyword>
	<keyword>non-alcoholic steatohepatitis</keyword>
	<keyword>NASH</keyword>
	<keyword>phase 2</keyword>
	<keyword>adaptive design</keyword>
	<keyword>randomized</keyword>
</DOC>